All Posts in "Uncategorized"

Unlocking 2024’s Hot Lithium Project: Li Resource Expanded by 175%

With a Worldwide Lithium Shortage by 2025 and Demand Set to Double by 2030, a World-Class Project in Argentina Developed by Lithium South (TSXV:LIS) (OTC:LISMF) is on Pace to Become Another High-Value Gem in the Lithium Pack

 

A worldwide battle to secure tomorrow’s energy future is underway today, as countries everywhere race to get their hands on a limited supply of lithium.

Not only are analysts sounding the alarm because a worldwide shortage of the metal being predicted by 2025[1], but also that by 2030 lithium demand is set to reach 2.4 million tonnes LCE[2] — Lithium consumption has already nearly quadrupled since 2010[3], and it doesn’t look at all like that trend is going to change any time soon.[4]

Experts estimate that meeting this demand will require at least US$42 billion in new investment to accomplish[5], and that by 2028, the global lithium market is expected to reach US$8.2 billion.[6]

However, where and how that money is spent is still up in the air. Right now there are several critics who are concerned with how lithium is produced, and how sustainable the industry is as a whole.[7]

Located next to two major lithium operations in the renowned Lithium Triangle, Lithium South Development Corporation (TSXV:LIS) (OTC:LISMF) recently increased its LCE Resource by 175% at its world-class HMN Li project in the heart of the Lithium Triangle,  LIS is quickly moving form being a lithium explorer to a lithium developer.

With production wells currently being installed at both the Alba Sabrina and Natalia Maria claim blocks on the project, Lithium South is processing test work, and pilot plant construction that would allow the HMN Li Project to have a Feasibility Study in early this year (2024).

Now equipped with a newly signed Cooperative Development Agreement with South Korean industry giant POSCO, they will have support through jointly developing two of the HMN Li Project’s most promising claim blocks.[8]

Let’s now take a deeper look into why Lithium South Development (TSXV:LIS) (OTC:LISMF) is in a great position to become one of the world’s next big lithium producers in the not-so-distant future…

8 Reasons Why Lithium South Development Corporation (TSXV:LIS) (OTC:LISMF) is Primed to Become a Major Contributor in the Lithium Industry

  1. Top-Notch Real Estate: The 100%-owned HMN Li Project is located in Salta Province spanning a package of 5,687 hectares located directly adjacent to a $4-billion project developed by POSCO (who has signed a Cooperative Development Agreement to jointly develop HMN Li brines). The project comes with good weather, an ideal location for evaporation extraction, a potentially sustainable water source, a gas pipeline near the property, and environmental permitting that is nearing completion.
  1. The Lithium M&A Market is HOT: Recent Acquisitions in the lithium space have been going for between US$227-962 million, meaning valuations are on the rise.[9],[10],[11],[12],[13],[14]
  1. Successful Resource Expansion Track Record: Thanks to a recent drill program, Lithium South succeeded in expanding the LCE resource on the HMN Li Project by 175% to a 1.57 million tonnes lithium carbonate equivalent[15], with 90% of the resource in the Measured category (the highest resource category).
  1. Pilot Plant and Pumping Wells Underway: A well drilling campaign is already underway for pumping/production wells to establish well flow. Evaporation test work is underway to validate this low-cost option. Due to the quality of the brine, recovery rates are anticipated to approach 70% (subject to QP certification) which would be high for this recovery method.[16]
  1. Upcoming Feasibility Study: Once the pumping tests are completed, results will be provided for analysis to deliver key information for the upcoming Feasibility Study which is expected in early 2024.
  1. Potential Revaluation Possibilities: With recent consolidation on the salar, Lithium South has Galan, POSCO, and the new Livent/Allkem merger entity as its neighbors, and with POSCO spending US$4B to develop their lithium production directly adjacent to LIS’s claim package, the company could potentially be revalued in relation to its peers.
  1. Proven Extraction Possibilities: Lithium South is evaluating low risk, industry proven evaporation extraction for its HMN Li Project. A network of ponds has been constructed (https://www.lithiumsouth.com) to prove the process. And technical expertise has been brought on board to “ optimize “ the extraction process to increase recovery to potentially 70%.
  1. Friends in High Places: Lithium South has recently signed a new cooperative development agreement with South Korean industry giant POSCO, representing a significant milestone in the development of HMN Li, including jointly developing two claim blocks on a 50/50 brine share basis, showcasing a spirit of partnership and pragmatism.

How Does Lithium South Development (TSXV:LIS) (OTC:LISMF) Stack Up With Its Neighbors?

Lithium South Development’s (TSXV:LIS) (OTC:LISMF)HMN Li Project is in great company, and surrounded by several major projects. Where the smart investor will now pay close attention is towards where the company is now, where it’s going, and how it will get there.

Lithium South has wasted no time in getting things ready, having already worked to greatly increase the project’s resource estimate, and is now in the process of putting in a pilot plant and pumping wells.

As the project advances, it’s worth noting the more advanced projects nearby, and how their progress might be able to give a glimpse of where HMN Li may be headed.

THE POSCO FACTOR

To get an idea of scale, one can look no further than the nearby lithium brine operation of South Korean steelmaking giant POSCO, which in 2022 announced a significant investment of US$4 billion into their project in the same Salar de Hombre Muerto as Lithium South. In June 2023, POSCO made a US$800M investment into the project to move it closer to production[17] and in September 2023, pledged another US$1.7 billion investment in Argentina[18].

At the POSCO project (named Sal de Oro)[19], it’s anticipated to initially produce 25,000 tonnes of lithium hydroxide annually, before expanding up to 100,000 tonnes annually—and the company hopes to commence operations in early-to-mid 2024.[20]

Prior to POSCO paying $ US 280 million to Galaxy Resources to acquire the project, the previous owners had named the project Sal de Vida, and had put out an updated 2018 Feasibility Study[21],  when lithium prices were half price compared to today. It provided the following highlights:

  • NPV of US$1.48 billion at an 8% discount rate
  • IRR of 26.9% with post-tax payback period of ~3 years from first production
  • JORC-compliant reserve estimate of 1.1 million tonnes of recoverable lithium carbonate equivalent (“LCE”) to support a long initial project life with 25ktpa of lithium carbonate and 94ktpa of potash production respectively
  • LCE Mineral Resource Estimate of 7.232 Mt LCE (M+Ind+Inf) at average grade of 753 mg/L or ppm
    • 565,000 tonnes LCE in Measured category
    • 119 Mt of potassium at 8,377 mg/L or ppm

Now although Lithium South is still in the process of preparing a Feasibility Study in 2024, in 2019 the company put out a Preliminary Economic Assessment[22] and by piecing that together with recently updated mineral resource estimates[23], we get the following highlights:

  • Post-Tax NPV of US$217M
  • IRR of 27.7% with pay-back period of 2.7 years
  • 5831 Mt LCE
    • 90% of resource in Measured category (~1.425Mt LCE)
    • Average grade 736 mg/L Li

Lithium South is currently working on an updated PEA which will use a much higher forward lithium price than the $ 12,400 per tonne used in 2019, , as well as preparing for a Feasibility Study that is expected to be delivered in 2024.

Now early in 2024, the proximity of the HMN Li Project to POSCO has become even closer. Because both Lithium South’s and POSCO’s assets hold claims to the same ground but in different Argentinian provinces, the two have come to a Cooperative Development Agreement to jointly develop two prominent HMN Li claim blocks on a 50/50 brine share basis.

This collaboration signifies a strategic advancement, particularly in the development of the Norma Edit and Viamonte claim blocks. Addressing historical provincial title issues, this partnership is key to tapping into the latent potential of these areas. With POSCO’s involvement, known for its robust presence in the lithium and steel industries, Lithium South fortifies its position in the market, underscoring its commitment to sustainable energy solutions.

TECPETROL GOES ALL IN ON ALLI

Another nearby property that’s worth consideration is that of Alpha Lithium and its Tolillar property which was developed and grown to its present state of a respectable mineral resource of 2.1 Mt LCE Indicated and another 1.2 Mt LCE Inferred.

The project’s potential garnered enough attention to entice Tecpetrol (a subsidiary of the Techint Group) to offer a premium all-cash proposal to acquire Alpha Lithium for a whopping C$273M (~US$199M)[24]. The deal was approved and finalized before the end of 2023[25].

WHAT DOES THIS POTENTIALLY MEAN FOR LIS?

Even if Lithium South Development (TSXV:LIS) (OTC:LISMF) doesn’t take the project all the way to production on its own, it’s surrounded by stories of major takeout target successes.

According to the company’s calculations, the HMN Li Project is near the top tier in terms of grade and chemistry, meaning it not only has a high grade of lithium that’s ahead of several other big players and their massive projects, but also that it comes with a favourably low magnesium to lithium ratio.

As of January 10, 2024, some might say that Lithium South Development’s (TSXV:LIS) (OTC:LISMF)stock value is still undervalued—given that the company’s market cap is less than US$34M, and nearby projects acquired were sold for upwards of 9 digits.

The relevance of Lithium South’s high lithium grades cannot be overstated.

Even if we’re looking at conventional brine evaporation ponds, lithium grade effects the size of the ponds. The higher the grade the smaller the pond. Pond size accounts for nearly 50% of the CAPEX of a brine project.

Meaning, the higher the grade, the lower the CAPEX.

Where does Lithium South’s HMN Li stack up amongst its peers?

It’s worth putting the HMN Li project together with peers, and to use our own discretion in deciding if the current valuation for Lithium South is fair or not.

Below is a table of peers with similar promising lithium projects:

Company Symbol Share Price (USD) Mkt Cap (USD) Primary Lithium Assets
Lithium South Development TSXV:LIS

OTC:LISMF

 $0.35 $33.5M HMN Li

1.58Mt LCE @ 736 mg/L Li
Argentina Lithium & Energy Corp. TSXV:LIT

OTC:LILIF

 $0.25 $31.7M Rincon West

Antofalla North

Pocitos

Incahuasi

 

(NO RESOURCE CALCULATION TO DATE)
Galan Lithium OTC:GLNLF $0.45 $159M Hombre Muerto West and Candelas
7.3Mt LCE @ 852 mg/L Li[26]
POSCO Holdings NYSE:PKX $85.54 $26.3B Sol de Oro

7.2Mt LCE @ 753 mg/L Li
*share price and market cap taken from Yahoo! Finance on January 10, 2024

Strong Leadership Team

In order to properly assess and work with a potentially game-changing technology in one of the world’s top lithium production regions, the HMN Li project requires capable hands… Thankfully, Lithium South Development (TSXV:LIS) (OTC:LISMF) is in VERY capable hands.

LIS’s leadership team includes:

Adrian F. C. Hobkirk – President and CEO: Hobkirk has 32 years of experience in the mining and venture capital industry, including extensive experience working in Argentina. He is the co-discoverer of the Dublin Gulch Gold Deposit (Yukon) and the Yarnell Gold Mine (Arizona). He’s explored for precious metals around the world, with LIS being his first venture into lithium.\. Hobkirk is the founder of Lithium South Development Corp., having acquired the HMN Lithium Project and managed its development to date. 

Christopher P. Cherry – CFO and Director: Cherry has over 20 years of corporate accounting and audit experience. Formerly an auditor with KPMG, he has extensive corporate experience and has held senior-level positions for several public mining companies. Cherry is a certified general accountant and a chartered accountant.

Yi Hua Dai, PhD – Director: Yi Hua (PhD) founded Chemphys in 1998 to focus on battery quality and high purity lithium processing. He’s a certified Technical and Economic Expert of Sichuan Province and China Non-ferrous Metals Industry Association Expert. He has a proven record of leading the development of lithium manufacturing techniques with 24 patents valid and under application.

Alison Dai – Director: Dai has 9 years of experience in the lithium industry and is responsible for business development and is a director for Chengdu Chemphys Chemical Industry Co., Ltd. In her role at Chemphys, Dai has been involved in developing strategic partnerships, international markets and procurement. Prior to joining Chemphys, Dai was an investment banking analyst at J.P. Morgan Australia in the mining and metals team.

Fernando E. Villarroel – VP & Director Project Development: Villarroel has 12 years of experience in the mining industry in Argentina with a focus on Lithium process development. From 2009 to 2013 he worked with Lithium Americas Corp. (Minera Exar S.A.) as Project Manager which included construction management and commissioning of the initial pilot evaporation facilities and laboratory at the Cauchari Olaroz Lithium Project. He has also acted as a consultant to Neo Lithium and International Lithium Inc. He holds a degree in Industrial Engineering and has specialized training in Data Modeling & Analysis for Business and Engineering from M.I.T.

Vijay Mehta, PhD. – Technical Consultant and Qualified Person: A recognized expert in lithium mining and processing, Dr. Mehta (PhD) brings almost five decades of experience to LIS. His experience includes evaluating the technological and economic feasibility of lithium brine projects around the world. He was the Product and Process Technology Development Leader of FMC Corporation for 30 years and was one of the founding developers of FMC’s lithium plant at the Hombre Muerto Salar, Argentina, which has been in production since 1998. He holds 12 lithium related U.S. patents and has published over 50 technology reports and ten academic papers.

 8 Reasons to Put Lithium South Development (TSXV:LIS) (OTC:LISMF) on Your Must-Watch List

 1  Top-Notch Real Estate

2  The Lithium M&A Market is HOT

3  Successful Resource Expansion Track Record

4  Pilot Plant and Pumping Wells Underway

5  Upcoming Feasibility Study

6  Potential Revaluation

7  Extraction Possibilities

8  Cooperative Development Agreement with POSCO

BEFORE YOU GO!

Now that you’ve digested the fruits of our research, it’s time to follow up with some research of your own.

NOW IS THE PERFECT TIME for smart investors to seriously follow the rapidly evolving Lithium South Development (TSXV:LIS) (OTC:LISMF) story.

LIS recently successfully expanded its already impressive resource in one of the world’s most sought after lithium jurisdictions. Other lithium assets in the region are being acquired at premium prices, and send a signal that Lithium South could very well be holding a highly-sought-after asset of its own in the very near future.

So, do your own due diligence, and don’t forget to click here to sign up for the Lithium South’s newsletter to make sure you don’t miss out on any news and milestones along the way to becoming the next darling of the lithium sector.

Mr. William Feyerabend, a Consulting Geologist and Qualified Person under NI 43-101, participated in the production of this advertisement and approves of the technical an scientific disclosure contained herein.

USA News Group
Editorial Staff

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Lithium South Development Corporation advertising and digital media from the company directly. There may be 3rd parties who may have shares of Lithium South Development Corporation, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Lithium South Development Corporation which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares Lithium South Development Corporation at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Lithium South Development Corporation and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED

[1] https://www.cnbc.com/2023/08/29/a-worldwide-lithium-shortage-could-come-as-soon-as-2025.html

[2] https://www.mining.com/global-lithium-production-hits-record-high-on-electric-vehicle-demand/

[3] https://elements.visualcapitalist.com/lithium-consumption-has-nearly-quadrupled-since-2010/

[4] https://www.fastmarkets.com/insights/lithium-demand-to-remain-unchanged

[5] https://www.benchmarkminerals.com/membership/analysis-lithium-industry-needs-42-billion-to-meet-2030-demand/

[6] https://www.globenewswire.com/en/news-release/2022/03/11/2401706/29442/en/Global-Lithium-Market-Expected-to-Reach-8-2-Billion-by-2028-Grand-View-Research-Inc.html

[7] https://www.investopedia.com/investing/lithium-mining-dirty-investment-or-sustainable-business/

[8] https://www.prnewswire.com/news-releases/lithium-south-announces-cooperative-development-agreement-with-posco-argentina-sau-on-hmn-li-project-302031863.html

[9] https://cassels.com/rep_work/lithium-americas-acquires-millennial-lithium-for-491-million/#:~:text=On%20January%2025%2C%202022%2C%20Lithium,)%2C%20for%20approximately%20%24491%20million.

[10] https://www.torys.com/en/work/2021/10/ac32c619-adf6-4296-948e-c715f7cd7e55

[11] https://www.riotinto.com/news/releases/2022/Rio-Tinto-completes-acquisition-of-Rincon-lithium-project

[12] https://www.reuters.com/markets/deals/chinas-ganfeng-lithium-buy-lithea-inc-962-mln-2022-07-11/

[13] https://www.spglobal.com/marketintelligence/en/news-insights/trending/BMkeaW0fipj15tymy_shQg2

[14] https://www.mining-technology.com/news/lithium-americas-purchase-arena/#:~:text=Lithium%20Americas%20has%20concluded%20the,the%20business%20at%20%24227m

[15] https://finance.yahoo.com/news/175-increase-lithium-120000123.html

[16] https://www.lithiumsouth.com/projects/

[17] https://thedalesreport.com/trends/south-korean-mining-giant-posco-to-invest-800m-in-its-sal-de-oro-lithium-project-in-argentina/

[18] https://en.mercopress.com/2023/09/04/posco-pledges-us-1.7-bn-investment-in-argentina

[19] http://www.poscoargentina.com/en

[20] https://smallcaps.com.au/posco-invests-developing-project-world-renowned-lithium-triangle/

[21] https://www.miningdataonline.com/reports/Sal_de_Vida_FS_2018.pdf

[22] https://www.lithiumsouth.com/wp-content/uploads/HMN-Final-Report-190808.pdf

[23] https://finance.yahoo.com/news/175-increase-lithium-120000425.html

[24] https://www.prnewswire.com/news-releases/tecpetrol-urges-alpha-lithium-shareholders-to-tender-as-soon-as-possible-following-positive-recommendation-by-the-alpha-board-of-directors-ahead-of-bid-deadline-of-3-october-2023-301942623.html

[25] https://www.globenewswire.com/news-release/2023/12/15/2796802/0/en/Alpha-Lithium-Shareholders-Approve-the-Privatization-of-Alpha-Lithium-by-Tecpetrol.html

[26] https://galanlithium.com.au/august-2023-diggers-and-dealers-presentation/

Editorial Staff by — April 27, 2024 By Editorial Staff in Uncategorized
Why Pancreatic Cancer is Targeting Younger Generations and How Pharma Giants are Responding

After an Astounding Surge in Patient Response Rate in their GOBLET Study and Earning an FDA Fast Track Designation, Wall Street Analysts are Touting Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) as a Universal STRONG BUY Rating, and Eyeing a Potential $15.00 Price Target (Currently at $2.20). Don’t Miss this Chance to Explore this Rising Star in Cancer Research. Get Ahead of this News TODAY!

Cancer is gripping the headlines and our lives with a frightening new urgency. Once a concern mainly for older adults, startling data reveals that early-onset cancer rates have surged 79% among those aged 15 to 49 since 1990.[1], [2]

It’s a crisis in plain sight, affecting younger generations at an alarming rate.

Take pancreatic cancer as a harrowing example. This year alone, an estimated 64,050 Americans will be diagnosed with this deadly disease, and tragically, over 50,000 will not survive.[3]

The trend is especially stark among young women, most notably in the Black community.[4] Clearly, the need for innovative cancer treatments is reaching a fever pitch.

The pharmaceutical landscape is taking note of this crisis. Big players like AstraZeneca, Roche, and Pfizer are pouring billions into acquisitions of biotech firms pioneering groundbreaking cancer treatments. [5],[6],[7],[8],[9],[10]

The focus is on powerful, targeted drugs that could rewrite the narrative of this debilitating illness.

In this critical landscape, one company has recently received significant validation for its contributions to pancreatic cancer research:

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)

 

Not only has it been awarded a $5M grant[11] from PanCAN, the Pancreatic Cancer Action Network, but its flagship asset, pelareorep, has also been selected for PanCAN’s ground-breaking Precision Promise pivotal Phase 3 clinical trial.

Now, with the $5M grant in hand, Oncolytics Biotech can continue the next stage of its research focused pelareorep, including pursuing a new combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. Previous to the award, ONCY successfully raised another US$15 million in order to continue the advancement of its pelareorep clinical programs in both pancreatic and metastatic breast cancers, with significant support from an institutional investor.[12]

Late in 2022, pelareorep earned the FDA’s Fast Track Designation[13] for treating advanced/metastatic pancreatic cancer.

With promising drug trials, impressive presentations on the horizon, and an industry ripe for their advancements, let’s now take a deeper look at Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)—a small company ready to take a giant leap in the fight against cancer.

8 Reasons Why Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and Pelareorep Could Be Big News in Cancer Treatment

1 Top-Notch Collaborations: Pelareorep is attracting big names in the business. Not only have they been selected by PanCAN to feature in a pivotal Phase 3 clinical trial, but they’re also teaming up with well-known companies like Pfizer, Merck KGaA, Roche, and Adlai Nortye. They’re also working with Merck & Co., Bristol-Myers Squibb, and Incyte.

2 Better Response Rate: Pelareorep’s response rate in pancreatic cancer is nearly 3X better than existing treatments[14]. This means it helped more patients fight off their cancer more effectively.

3 Complete Response Recorded: A complete response is when the cancer disappears entirely. This is a big deal. It happened to 1 out of 13 pancreatic cancer patients in the GOBLET study treated with pelareorep. That’s a MUCH higher rate than a previous trial[15] that had just one complete response out of 861 patients.

4 Fast Track Stamp: The FDA has given pelareorep a ‘Fast Track’ designation. This means the treatment could be available sooner to those who need it most. The FDA is fast-tracking pelareorep’s use with another cancer drug called atezolizumab and chemotherapy for advanced pancreatic cancer.

5 Boosting Other Treatments: Pelareorep can be used with immune checkpoint inhibitors (ICI), a type of drug that can be effective in fighting cancer, but only works for some people. Pelareorep might help more patients benefit from these inhibitors. The ICI market is expected to hit around US$168.76 billion by 2032[16], despite as few as 1 in 5 patients responding to ICI therapy[17].

6 Exciting Data on the Horizon: Oncolytics Biotech has already shared promising data about pelareorep, and there’s more to come. They are expected to deliver new information from their colorectal cancer and pancreatic cancer cohorts of the GOBLET trial in the second half of 2023, which many believe could lead to further advances. As well, pelareorep was chosen for inclusion in PanCAN’s Precision PromiseSM pivotal phase 3 platform trial, which is expected to open in early 2024.

7 Experienced Team: The team behind pelareorep knows what they’re doing. They have over 150 years of combined experience in drug development and the biopharmaceutical industry.

8 Well-Funded: Oncolytics Biotech is in a good financial position. Now with a recent $5M grant award from PanCAN, and an additional US$15M raised with the support of a significant institutional investor, they have enough money to cover their key projects for the next 12 months and beyond.

The Experts’ Verdict: A Strong Buy

According to the consensus of analyst ratings on NASDAQ.com, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is receiving a STRONG BUY rating from experts.[18] With an average price target of $7.73 and a high estimate of $15, they’re expecting a significant jump from its current share price of ~$2.20 as of September 29, 2023­­.

That’s a potential-high projected growth of nearly 6x its current price, or an increase of +580%!

So, what are these analysts seeing that the rest of the market might be missing?

While we can’t speak for them, we believe it should be crystal clear by now why ONCY is one of the most promising opportunities we’ve spotted in years.

You’ve already seen why Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is a star in the making,  what’s coming down the pipeline very soon, and why NOW is the ideal time for investors to take action.

Big Pharma -> Big Cancer Investments

In the ever-evolving landscape of cancer treatment, pharmaceutical giants are making monumental moves.

For example, Pfizer acquired Trillium for $2.3 billion[19], a firm that has developed two innovative drugs aimed at boosting the body’s natural defenses against cancer. They didn’t stop there; Pfizer also shelled out $43 billion[20] to acquire Seagen, another pioneer in cancer treatment solutions.

Not to be outdone, Amgen is on the brink of closing a $27.8 billion deal[21] with Horizon Therapeutics. Horizon caught everyone’s attention by crossing significant FDA hurdles with their new cancer drug[22]. Similarly, Takeda, a behemoth in Japan, is collaborating with Hutchmed from Hong Kong, dedicating up to $1.13 billion[23] in developing a colorectal cancer drug. This indicates that the race for effective treatments is a global pursuit.

AstraZeneca is making waves as well, with their drug, Enhertu, gaining praise for its effectiveness against breast cancer. [24] The drug is nearly twice as effective as other treatments, revolutionizing expectations for patient outcomes.

Sanofi is also throwing its hat into the ring, having acquired Synthorx for $2.5 billion[25]. This purchase gives Sanofi access to a drug that takes the best parts of older treatments while eliminating the negative side effects.

Last but not least, Roche’s acquisition of Genentech for $47 billion back in 2009 has paid off significantly. Genentech’s portfolio of top-selling cancer drugs escalated from $7 billion in 2008 to a staggering $21 billion by 2018. [26]

What does this mean for Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)?

It means that Oncolytics is well-positioned to become a crucial player in this competitive and rapidly expanding landscape. With their flagship asset, pelareorep, already selected for the PanCAN Precision Promise pivotal Phase 3 clinical trial, the company is on the brink of groundbreaking advancements in pancreatic cancer treatment.

What’s more, PanCAN’s recent $5 million grant award underscores the promise and potential of pelareorep, solidifying its role as a catalyst for innovation in the fight against this devastating disease.

The pattern is clear: pharmaceutical titans are willing to invest billions to acquire companies with promising cancer treatment assets. Given Oncolytics Biotech’s emerging success, especially in the realm of pancreatic cancer—a disease with rising incidence rates in younger populations—the company could very well be on the radar for potential acquisition by industry giants. It’s not just about the money; it’s about the accelerating need for effective treatments and the companies that are agile and innovative enough to meet that demand.

ONCY Among Its Peers

Now let’s look at how Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) stacks up to its peers as a potential takeout target in the future by pharma giants looking for an oncology winner:

*Share price and market cap taken from Yahoo Finance on midday September 29, 2023

In the world of cancer treatment, companies are always racing to find the next big thing. Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) stands out in this busy field, and here’s why.

Share Price & Market Cap

First, let’s talk numbers. Oncolytics Biotech has a share price of $2.17 and a market cap of $159 million. That’s a pretty strong position compared to companies like Defence Therapeutics and CytomX Therapeutics, whose market caps are approximately $100 million. It means Oncolytics has more financial muscle to push its research and grow its business.

Treatment Focus

Oncolytics is working on an “immunotherapeutic agent,” which is a fancy way of saying it helps your body’s defense system fight cancer better. This is a hot area in cancer research, attracting big investments and interest from pharma giants. Some companies like Autolus Therapeutics are focused on CAR T Cell Therapies, but these are still being tested and could have years to go before getting the final nod from health authorities, whereas pelareorep is already well underway and on the FDA’s radar, having already received Fast Track Designation for breast cancer and pancreatic cancer.

Recent Achievements

Let’s not forget Oncolytics was recently awarded a $5 million grant from PanCAN and was chosen for a critical Phase 3 trial. This shows the industry believes in what Oncolytics is doing and puts the company in a prime spot for future growth or even being bought out by a bigger fish in the pond.

The Bigger Picture

Companies like Biomea Fusion might have a higher market cap ($484.2 million), but they’re focusing on “covalent small molecules,” a different arena from Oncolytics’ focus on immunotherapeutic agents. Different doesn’t mean better, and given the urgency around finding effective cancer treatments, Oncolytics’ direction seems very promising.

Pelareorep vs Pancreatic Cancer

The Urgent Need for Better Pancreatic Cancer Treatments

Pancreatic cancer is one of the deadliest forms of cancer, requiring urgent attention for effective treatments. Sadly, only about 11.5% of patients survive beyond five years after diagnosis, according to the U.S. National Cancer Institute. Estimates suggest that by 2028, approximately 135,000 people in major markets will need treatment for advanced or metastatic pancreatic cancer[27].

Limited Efficacy of Existing Therapies

Current treatments, such as chemotherapy, show limited effectiveness. For example, when gemcitabine and nab-paclitaxel are used as the first line of defense against pancreatic cancer, they shrink the tumor in only about 25% of cases[28]. Immune checkpoint inhibitors (ICIs) only work for less than 1% of patients[29], highlighting the desperate need for improved options.

Stunning Results from the GOBLET Study

The GOBLET study, a critical investigation into pelareorep’s effectiveness when combined with atezolizumab (an immune checkpoint inhibitor) and chemotherapy, is painting an extraordinary picture. What’s been unveiled so far is nothing short of remarkable: an unprecedented 69% response rate in the initial batch of evaluated patients.

To fully understand the magnitude of this breakthrough, let’s put it in perspective. Compared to the usual 25% response rate observed with chemotherapy mentioned above, this skyrockets way above the norm, nearly tripling the success rate. It’s not just about the numbers. It’s about the real, tangible hope this offers to patients who have been in dire need of more effective solutions.

PanCAN’s Precision Promise Inclusion

These achievements have not gone unrecognized, as the Pancreatic Cancer Action Network (PanCAN) officially selected pelareorep for inclusion in its innovative adaptive Phase 3 clinical trial, Precision PromiseSM[30]. The Precision Promise study is designed to evaluate pelareorep in combination with a checkpoint inhibitor and the chemotherapeutic agents gemcitabine and nab-paclitaxel. This novel trial is expected to minimize the number of patients required to generate licensure-enabling data, accelerate development, reduce costs compared to a traditional trial, and support approval as a treatment for first-line metastatic pancreatic ductal adenocarcinoma.

Oncolytics expects to open the Precision Promise investigational treatment of pelareorep, a checkpoint inhibitor, gemcitabine, and nab-paclitaxel in early 2024.

As well, PanCAN has recently signaled its level of confidence in pelareorep, by awarding Oncolytics with a $5M grant, to help push further research.

Pelareorep’s FDA Record

FDA Fast Track Designation: A Significant Achievement for Oncolytics Biotech

Recognizing the ground-breaking results from the GOBLET study, the FDA awarded Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) a Fast Track designation in December 2022. This decision came on the heels of Oncolytics’ presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, where they showcased the remarkable 69% objective response rate.

Fast Track designation is a significant milestone. It’s specifically designed to speed up the development and review of therapies that can treat severe conditions and address unmet medical needs. For a therapy to earn this privilege, it has to show a substantial advantage over existing treatments. Pelareorep, demonstrating nearly triple the average response rate compared to existing treatments, fits this bill impressively.

“This Fast Track designation is an important accomplishment that speaks to the impressive response rate and the durability of the response in our PDAC study. It also reflects the pressing need to improve upon the standard of care in this indication. We are excited for what’s ahead.”

– Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc.

Indeed, this designation adds another feather in Oncolytics’ cap, marking a pivotal moment in their journey to bring forward a more effective treatment for pancreatic cancer. As the GOBLET study continues, the anticipation for more positive outcomes grows, and with it, the promise of pelareorep transforming the landscape of cancer treatment.

MEET THE EXPERTS AT ONCOLYTICS BIOTECH

Getting a new medical treatment like pelareorep ready for patients involves many steps and a skilled team. The experts at Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) are just the right people for the job. They have worked at leading companies and universities, such as Amgen, Bristol-Myers Squibb, and Harvard Medical School.

Let’s meet some of them:

Matt Coffey, PhD, MBA – Co-Founder, Director, President & CEO
Dr. Coffey is a cancer expert who has studied how a virus can help fight cancer. His research has been published in many notable scientific journals.

Thomas Heineman, MD, PhD – Head of Clinical Development and Operations
Dr. Heineman is a medical doctor who has spent over 25 years developing new drugs. He’s worked on projects for many types of cancer, including breast and pancreatic cancer, at places like GSK.

Andrew de Guttadauro – Global Head of Business Development
Mr. de Guttadauro has spent over 25 years helping new medical treatments reach patients. He has been a leader at big companies like Vical and Amgen.

Wayne Pisano, MBA – Chair of the Board
Pisano is an award-winning leader in the field of vaccines. He used to be the head of Sanofi Pasteur, one of the biggest vaccine companies in the world.

There are many other talented people at Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)  too, from their other leaders to their Board of Directors and Scientific Advisory Board. They have worked at top companies and institutions like Ernst & Young LLP, Amgen, and Princeton University.

For example, Deborah M. Brown, B.Sc., M.B.A. is a Director who helps new medical businesses grow. She’s worked at EMD Serono and is now a leader at Accelera Canada.

Another Director, Bernd R. Seizinger, MD, PhD, is an expert in cancer drug discovery. He’s worked at Bristol-Myers Squibb and held top roles at Harvard Medical School and Princeton University. He’s now on the board of several biotech companies.

In short, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is guided by some of the best minds in the business.

RECAP: 8 Take Aways for
Oncolytics Biotech Inc.
(NASDAQ:ONCY) (TSX:ONC)

1.  Top-Notch Collaborations

2.  Better Response Rate

3.  Complete Response Recorded

4.  Fast Track Granted

5.  Boosting Other Treatments

6.  Exciting Data on the Horizon

7.  Experienced Team

8.  Well-Funded

BEFORE YOU GO CLICK AWAY!

You’ve made it this far, so it’s clear you’re interested. With big events on the horizon and the progress we’ve already seen, we think NOW IS THE RIGHT MOMENT for savvy folks to keep a close eye on Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

So, take some time to do your own research, and don’t forget to sign up for email alerts. That way, you’ll stay updated on all the exciting news and milestones from ONCY. We’re here to keep you informed!

USA News Group
Editorial Staff

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

[1] https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00039-0/fulltext

[2] https://globalnews.ca/news/9938796/cancer-cases-young-adults-study/

[3] https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html#:~:text=of%20pancreatic%20cancer-,How%20common%20is%20pancreatic%20cancer%3F,will%20die%20of%20pancreatic%20cancer.

[4] https://www.cedars-sinai.org/newsroom/study-confirms-pancreatic-cancer-rates-rising-faster-in-women-than-men/

[5] https://www.reuters.com/breakingviews/super-chemo-will-be-big-pharmas-next-tussle-2022-05-16/

[6] https://www.forbes.com/sites/greatspeculations/2019/07/10/was-the-47-billion-acquisition-of-genentech-in-2009-a-good-deal-for-roche/?sh=5c78818aa1aa

[7] https://www.fiercebiotech.com/biotech/eat-me-pfizer-swallows-cd47-biotech-trillium-2-3b-takeover

[8] https://www.wsj.com/business/ftc-settles-with-amgen-over-27-8-billion-deal-for-horizon-therapeutics-b96a2d69

[9] https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-fda-approval-update

[10] https://www.fiercebiotech.com/biotech/sanofi-inks-2-5b-synthorx-takeover-to-gain-il-2-cancer-drug

[11] https://finance.yahoo.com/news/pancreatic-cancer-action-network-selects-120000574.html

[12] https://finance.yahoo.com/news/oncolytics-biotech-successfully-raises-us-125000351.html

[13] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-fda-fast-track-designation-for-the-treatment-of-advanced-metastatic-pancreatic-cancer/

[14] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-presents-updated-clinical-data-at-sitc-annual-meeting-showing-a-69-objective-response-rate-and-confirmed-complete-response-in-goblet-studys-pancreatic-cancer-cohort/

[15] https://www.nejm.org/doi/full/10.1056/nejmoa1304369

[16] https://www.precedenceresearch.com/immune-checkpoint-inhibitors-market#:~:text=The%20global%20immune%20checkpoint%20inhibitors,forecast%20period%202023%20to%202032

[17] JAMA Netw Open. 2019 May; 2(5): e192535

[18] https://www.nasdaq.com/market-activity/stocks/oncy/analyst-research

[19] https://www.fiercebiotech.com/biotech/eat-me-pfizer-swallows-cd47-biotech-trillium-2-3b-takeover

[20] https://www.aljazeera.com/news/2023/3/13/pfizer-buys-seagen-for-43bn-boosts-access-to-cancer-drugs

[21] https://www.wsj.com/business/ftc-settles-with-amgen-over-27-8-billion-deal-for-horizon-therapeutics-b96a2d69

[22] https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-fda-approval-update

[23] https://www.fiercepharma.com/pharma/takeda-makes-113m-deal-hutchmed-cancer-drug-fruquintinib

[24] https://www.reuters.com/breakingviews/super-chemo-will-be-big-pharmas-next-tussle-2022-05-16/

[25] https://www.fiercebiotech.com/biotech/sanofi-inks-2-5b-synthorx-takeover-to-gain-il-2-cancer-drug

[26] https://www.forbes.com/sites/greatspeculations/2019/07/10/was-the-47-billion-acquisition-of-genentech-in-2009-a-good-deal-for-roche/?sh=5c78818aa1aa

[27] https://stockhouse.com/news/the-market-herald-news/2023/06/15/anatomy-flagship-asset-oncolytics-biotech-s-cancer-immunotherapy

[28] https://www.nejm.org/doi/full/10.1056/nejmoa1304369

[29] Luchini C, Brosens LAA, Wood LD, et al. Gut 2021;70:148–156

[30] https://finance.yahoo.com/news/oncolytics-biotechs-pelareorep-selected-inclusion-110000604.html

Editorial Staff by — April 27, 2024 By Editorial Staff in Uncategorized

With Lithium Demand Set to Double by 2030 and Drastically Outpacing New Supply, Lithium South Development (TSXV:LIS) (OTC:LISMF) is Poised with a World-Class Project and Potentially Sector Disrupting Technology to Lead the Way to a Sustainable ‘Gold Rush’ in Argentina

While lithium prices reach new highs, the lithium sector is battling a multi-front war against a wave of challenges: logistical, geopolitical, and environmental.

Analysts are sounding the alarm that while by 2030, lithium demand is set to reach 2.4 million tonnes LCE. [1] It’s not hard to believe in such a jump, as lithium consumption has already nearly quadrupled since 2010.[2]

Given that the worldwide supply of lithium is expected to hit 600,000 tonnes of LCE in 2022,[3] that means we have 6 years to quadruple our production to meet demand.

But getting there is proving to be a monumental task, especially with mounting environmental, geopolitical and technological challenges.[4]

Analysts estimate this will require at least US$42 billion in new investment to accomplish this feat.[5] By 2028, the global lithium market is expected to reach US$8.2 billion.[6]

Located next to two major lithium operations in the renowned Lithium Triangle, Lithium South Development (TSXV:LIS) (OTC:LISMF) is actively drilling to expand the M&I Resource of its world-class HMN Li project that’s at the center of a global race to prove the validity of the game-changing ESG-friendly lithium extraction process that the world has been waiting for.

RECENT NEWS HEADLINES:

Lithium South Development in 60 Seconds

  • Advanced exploration stage lithium company with a world-class project in the mining friendly Salta Province, Argentina—within the world-famous Lithium Triangle
  • Great Real Estate of the project that’s adjacent to production from Livent and surrounded by a near-production project owned by Korean giant POSCO.
  • High Quality Brine Resource with an M&I Resource of 570,000 tonnes of LCE, a projected mine life of 30 years, from high lithium brine with 756 mg/L lithium.
  • Solid PEA Numbers calculated in early 2019 indicated robust economics with a NPV (8% discount) of US$217 million, that carries a CAPEX of only US$98 million.
    • HOWEVER those numbers were calculated in 2019, before lithium prices went on a huge run, rising more than 13-fold in just the last two years.[7]
  • ESG-Friendly, Game-Changing Technology is being tested by three different entities in three different countries with brines sampled from the flagship asset, which to-date have returned extremely promising results (99% lithium recovery).
  • Staged & Work Completed with a promising 2022 drill campaign underway designed for resource expansion, that’s already returned high lithium brine results. An Environmental Impact Report has already been completed, and nearby claims have been acquired to secure additional water sources and a location for a future plant and processing facilities.
  • Qualified, Proven Team with extremely strong technical lithium experience that includes minds that were integral to the development of some of the region’s most prominent lithium production operations.

 

 

The Need for Clean(er) Lithium

Before we get to the core of the Lithium South Development (TSXV:LIS) (OTC:LISMF) story, we need to look at the most exciting technological race that’s taking the lithium sector by storm, and how LIS fits into it.

A new report from The Nature Conservancy (TNC) and UCLA recently outlined the need for prioritizing the least impactful methods of lithium extraction to protect the environment and communities.[8]

The questions being raised by TNC are important for markets, because of their reputation for input on assessing the worthiness of companies and “Investing in Nature” in this ESG-focused era.[9]

Voices are growing louder, calling for the methods we use to produce lithium to radically change.

A new lithium technology is drawing heavy investment from major players, such as mining giant Rio Tinto, automaker General Motors, and even the U.S. Energy Department, called direct lithium extraction (DLE).[10]

“[DLE is] such a game changer. There’s huge opportunities.” – U.S. Energy Secretary Jennifer Granholm[11]

Time Magazine recently pointed its readers towards a lithium race in Argentina that could deliver the country a “Sustainable Gold Rush”.[12]

Direct Lithium Extraction (DLE): The Answer?

Embedded within the Time Magazine report was a focus on the work of privately-owned, California-based start-up Lilac Solutions, which in 2021 raised $150 million from investors including Lowercarbon Capital and T. Rowe Price.[13]

This is where Lithium South Development’s (TSXV:LIS) (OTC:LISMF) HMN Li Project begins to shine.

In April 2021, Lilac and Lithium South generated huge optimism, announcing how Lilac’s patented Ion Exchange (IX) technology recovered 99% of the lithium from a synthetic sample of the HMN Li Project brine—identical in chemical composition to that contained within the project’s NI 43-101 Preliminary Economic Assessment (PEA).[14]

But it doesn’t stop there. Lithium South is working with two other groups (not just Lilac) to test the validity of DLE on the HMN Li project, including with Florida-based Eon Minerals Inc.[15] with its in Argentina and with Chemphys and their lab facilities in China.[16]

Using Chemphys’ XFP-Lithium DLE process, test work delivered 80% lithium recovery, which is a near doubling of lithium recovery rates from conventional evaporation extraction.[17]

These results from the DLE testing has been blowing conventional methods out of the water (even though Lithium South is prudently also testing conventional evaporation as a potential method to produce from HMN Li)[18].

How Does Lithium South Development (TSXV:LIS) (OTC:LISMF) Stack Up With Its Neighbors?

Lithium South Development’s (TSXV:LIS) (OTC:LISMF) HMN Li Project is in great company, and surrounded by several major projects.

The HMN Li already has moved forward with a DLE Pilot Plant on deck, a 2019 PEA that gave the project a US$218 million NPV (8%), and with C$64 million on hand, LIS is fully funded to fast-track towards a Feasibility Study.

Where the smart investor will now pay close attention is towards where the company is now, where it’s going, and how it will get there.

If it doesn’t take the project all the way to production on its own, it’s surrounded by stories of major takeout target successes.

According to the company’s calculations, the HMN Li Project is near the top tier in terms of grade and chemistry, meaning it not only has a high grade of lithium that’s ahead of several other big players and their massive projects, but also that it comes with a favourably low magnesium to lithium ratio.

With a M&I Resource of 571,000 T of LCE, the current drilling program is designed to further expand the resource.

And so far the results have looked VERY good.

Recently the company announced a high-grade lithium discovery at its Alba Sabrina claim, with lithium values ranging from 732-772 mg/L lithium[19]—very much on pace with the previous resource’s grades and far above the cut-off grade of 500 mg/L lithium.

Because the drilling campaign’s results are starting to hit the company’s news flow, this is where the smart investor would take notice and not want to be left on the outside looking in as the case for an expanded resource becomes much stronger.

As of August 12, 2022, some might say that Lithium South Development’s (TSXV:LIS) (OTC:LISMF) stock value is an absolute BARGAIN… given that the company’s market cap is less than US$40M, and nearby projects acquired were sold for upwards of 9 digits.

 

The relevance of Lithium South’s high lithium grades cannot be overstated.

Even if we’re looking at conventional brine evaporation ponds, lithium grade is directly related to the size of the ponds. These sizes of ponds account for nearly 50% of the CAPEX of a brine project.

Meaning, the higher the grade, the lower the CAPEX.

Where does Lithium South’s HMN Li stack up amongst its peers?

Now factor in the potential injection of the DLE factor, and the economics start looking even more enticing.

As we’ve seen above, Lilac delivered 99% lithium recovery, while Chemphys delivered 80% lithium recovery, which was DOUBLE that of conventional evaporation tests on the property.

Which means, if one of the three DLE methods ends up winning out, the potential for Lithium South and its flagship asset skyrockets.

Instead of taking 18 months or more to produce lithium through evaporation, Lithium South could potentially produce it within HOURS. Instead of recovering only ~40% of the overall lithium available, DLE could provide as high as 80% or more!

And the potential for losses due to weather goes down to ZERO. Meaning, the project further de-risks itself, should DLE prove itself to be a viable commercial method of producing lithium.

Strong Leadership Team

In order to properly assess and work with a potentially game-changing technology in one of the world’s top lithium production regions, the HMN Li project requires capable hands… Thankfully, Lithium South Development (TSXV:LIS) (OTC:LISMF) is in VERY capable hands.

LIS’s leadership team includes:

Adrian F. C. Hobkirk – President and CEO: Hobkirk has 32 years of experience in the mining and venture capital industry, including extensive experience working in Argentina. He is the co-discoverer of the Dublin Gulch Gold Deposit (Yukon) and the Yarnell Gold Mine (Arizona). He’s explored for precious metals around the world and is currently developing the 1.5-million-ounce AuCuEq Groete Gold Copper Project in Guyana. Hobkirk is the founder of Lithium South Development Corp., having acquired the HMN Lithium Project and managed its development to date.

 Christopher P. Cherry – CFO and Director: Cherry has over 20 years of corporate accounting and audit experience. Formerly an auditor with KPMG, he has extensive corporate experience and has held senior-level positions for several public mining companies. Cherry is a certified general accountant and a chartered accountant.

Yi Hua Dai, PhD – Director: Yi Hua (PhD) founded Chemphys in 1998 to focus on battery quality and high purity lithium processing. He’s a certified Technical and Economic Expert of Sichuan Province and China Non-ferrous Metals Industry Association Expert. He has a proven record of leading the development of lithium manufacturing techniques with 24 patents valid and under application.

Alison Dai – Director: Dai has 9 years of experience in the lithium industry and is responsible for business development and is a director for Chengdu Chemphys Chemical Industry Co., Ltd. In her role at Chemphys, Dai has been involved in developing strategic partnerships, international markets and procurement. Prior to joining Chemphys, Dai was an investment banking analyst at J.P. Morgan Australia in the mining and metals team.

Fernando E. Villarroel – VP & Director Project Development: Villarroel has 12 years of experience in the mining industry in Argentina with a focus on Lithium process development. From 2009 to 2013 he worked with Lithium Americas Corp. (Minera Exar S.A.) as Project Manager which included construction management and commissioning of the initial pilot evaporation facilities and laboratory at the Cauchari Olaroz Lithium Project. He has also acted as a consultant to Neo Lithium and International Lithium Inc. He holds a degree in Industrial Engineering and has specialized training in Data Modeling & Analysis for Business and Engineering from M.I.T.

Marcela Casini – Senior Geologist and Hydrogeologist: Casini has a distinguished career in the lithium exploration and development industry in Argentina, having worked for Rio Tinto as a field geologist exploring salars in the Puna region, as well as on the Minera Exar lithium brine project, a joint venture with Lithium Americas Corp. and Ganfeng Lithium Co, leading the exploration that led the project to the feasibility 2012. From 2019 to 2021 she was responsible for the strategy and development of the production well field, supporting a projected 40,000 tonne per year lithium operation. She’s also has consulted to PepinNini Minerals regarding the exploration and development of lithium resources at the Rincon and Pular salar since 2016.

Vijay Mehta, PhD. – Technical Consultant and Qualified Person: A recognized expert in lithium mining and processing, Dr. Mehta (PhD) brings almost five decades of experience to LIS. His experience includes evaluating the technological and economic feasibility of lithium brine projects around the world. He was the Product and Process Technology Development Leader of FMC Corporation for 30 years and was one of the founding developers of FMC’s lithium plant at the Hombre Muerto Salar, Argentina, which has been in production since 1998. He holds 12 lithium related U.S. patents and has published over 50 technology reports and ten academic papers.

7 Reasons to Put Lithium South Development (TSXV:LIS) (OTC:LISMF) on Your Must-Watch List

 1  The Timing: The lithium market is exploding, with prices skyrocketing over the last two years, and demand expected to more than double by the end of the decade. Meanwhile, analysts are predicting what could be a catastrophic shortfall of lithium supplies in the next few years, unless lithium miners can increase their production to four times its current levels.

 2  Advanced Exploration Stage Project with Great Real Estate: The HMLi Project is located within the mining friendly Salta Province, Argentina, adjacent to a producing Livent property, and surrounded by a near-producing project owned by Korean giant POSCO.

 3  High Quality Brine Resource: The project comes with high lithium brine (756 mg/L), with a low magnesium to lithium ratio (2.6:1), and a M&I Resource of 0.57 Mt LCE, and a projected mine life of 30 years.

 4  Solid PEA Numbers: So far, the PEA done on the project indicates robust economics, with a NPV (8% discount) of US$217 million, that carries a CAPEX of only US$98 million. However, those numbers were calculated in 2019, prior to lithium’s surge to its current LCE market prices that greatly dwarf those previous figures.

 5  Proprietary, ESG-Friendly Technology: Direct Lithium Extraction (DLE) is on the cutting edge of becoming one of the industry’s biggest game changers. It allows for potentially double the lithium recovery without large evaporation ponds. It takes hours, not years, and creates a much smaller environmental footprint, which would appease local communities in ways that conventional production has yet to. Lithium South is evaluating three different unique DLE technologies, as well as the potential for conventional production as a benchmark.

 6  Qualified Proven Team: Extremely strong technical lithium experience, with an office and laboratory located nearby in Salta, Argentina, backed by world-renowned technical consultant and qualified person Vijay Mehda, along with senior geologist/hydrologist Marcela Casini.

 7  Staged & Work Completed: Two production wells have already been drilled and cased. An Environmental Impact Report is currently underway. TEM survey results confirm further resource expansion potential. The company has aggressively acquired nearby claims to secure water sources and a location of future plant and processing facilities.

Now that you’ve digested the fruits of our research, it’s time to follow up with some research of your own.

NOW IS THE PERFECT TIME for smart investors to seriously follow the rapidly Lithium South Development (TSXV:LIS) (OTC:LISMF) story.

LIS is actively working to expand its already impressive resource in one of the world’s most sought after lithium jurisdictions, and is at the forefront of proving the viability of potentially industry changing DLE technology.

So, do your own due diligence, and don’t forget to click here to sign up for the Lithium South’s newsletter to make sure you don’t miss out on any news and milestones along the way to becoming the next darling of the lithium sector.

USA News Group
Editorial Staff

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Lithium South Development Corporation advertising and digital media from the company directly. There may be 3rd parties who may have shares of Lithium South Development Corporation, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Lithium South Development Corporation which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares Lithium South Development Corporation at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Lithium South Development Corporation and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

[1] https://www.mining.com/global-lithium-production-hits-record-high-on-electric-vehicle-demand/

[2] https://elements.visualcapitalist.com/lithium-consumption-has-nearly-quadrupled-since-2010/

[3] https://www.benchmarkminerals.com/membership/analysis-lithium-industry-needs-42-billion-to-meet-2030-demand/

[4] https://www.sciencedirect.com/science/article/abs/pii/S0959652621011732

[5] https://www.benchmarkminerals.com/membership/analysis-lithium-industry-needs-42-billion-to-meet-2030-demand/

[6] https://www.globenewswire.com/en/news-release/2022/03/11/2401706/29442/en/Global-Lithium-Market-Expected-to-Reach-8-2-Billion-by-2028-Grand-View-Research-Inc.html

[7] https://www.mining-technology.com/analysis/lithium-price-challenges/

[8] https://www.nature.org/en-us/newsroom/ca-lithium-extraction/

[9] https://www.nature.org/content/dam/tnc/nature/en/documents/TNC-INVESTING-IN-NATURE_Report_01.pdf

[10] https://www.reuters.com/business/sustainable-business/new-lithium-technology-can-help-world-go-green-if-it-works-2022-04-07/

[11] https://www.reuters.com/business/sustainable-business/new-lithium-technology-can-help-world-go-green-if-it-works-2022-04-07/

[12] https://time.com/6200372/lithium-mining-technology-argentina-gold/

[13] https://www.cnbc.com/2021/09/22/lilac-raised-150-million-for-sustainable-lithium-extraction-tech.html

[14] https://www.lithiumsouth.com/posts/lilac-solutions-achieves-99-lithium-recovery-with-ion-exchange-process/

[15] https://www.lithiumsouth.com/posts/eon-minerals-inc-to-evaluate-hmn-brine-using-direct-lithium-extraction-technology/

[16] https://www.prnewswire.com/news-releases/lithium-south-development-corporation-doubling-of-lithium-recovery-from-brine-with-chemphys-process-301248906.html

[17] https://www.lithiumsouth.com/posts/doubling-of-lithium-recovery-from-brine-with-chemphys-process/

[18] https://www.lithiumsouth.com/posts/evaporation-test-work-underway-at-hmn-li-project/

[19] https://www.lithiumsouth.com/posts/high-grade-lithium-discovery-at-alba-sabrina-claim-block/

Editor by — April 27, 2024 By Editor in Uncategorized
How a New Sustainable Lithium Production Technology Could Save the EV Revolution

With Lithium Demand Set to Double by 2030 and Drastically Outpacing New Supply, Lithium South Development (TSXV:LIS) (OTC:LISMF) is Poised with a World-Class Project and Potentially Sector Disrupting Technology to Lead the Way to a Sustainable ‘Gold Rush’ in Argentina

While lithium prices reach new highs, the lithium sector is battling a multi-front war against a wave of challenges: logistical, geopolitical, and environmental.

Analysts are sounding the alarm that while by 2030, lithium demand is set to reach 2.4 million tonnes LCE. [1] It’s not hard to believe in such a jump, as lithium consumption has already nearly quadrupled since 2010.[2]

Given that the worldwide supply of lithium is expected to hit 600,000 tonnes of LCE in 2022,[3] that means we have 6 years to quadruple our production to meet demand.

But getting there is proving to be a monumental task, especially with mounting environmental, geopolitical and technological challenges.[4]

Analysts estimate this will require at least US$42 billion in new investment to accomplish this feat.[5] By 2028, the global lithium market is expected to reach US$8.2 billion.[6]

Located next to two major lithium operations in the renowned Lithium Triangle, Lithium South Development (TSXV:LIS) (OTC:LISMF) is actively drilling to expand the M&I Resource of its world-class HMN Li project that’s at the center of a global race to prove the validity of the game-changing ESG-friendly lithium extraction process that the world has been waiting for.

RECENT NEWS HEADLINES:

Lithium South Development in 60 Seconds

  • Advanced exploration stage lithium company with a world-class project in the mining friendly Salta Province, Argentina—within the world-famous Lithium Triangle
  • Great Real Estate of the project that’s adjacent to production from Livent and surrounded by a near-production project owned by Korean giant POSCO.
  • High Quality Brine Resource with an M&I Resource of 570,000 tonnes of LCE, a projected mine life of 30 years, from high lithium brine with 756 mg/L lithium.
  • Solid PEA Numbers calculated in early 2019 indicated robust economics with a NPV (8% discount) of US$217 million, that carries a CAPEX of only US$98 million.
    • HOWEVER those numbers were calculated in 2019, before lithium prices went on a huge run, rising more than 13-fold in just the last two years.[7]
  • ESG-Friendly, Game-Changing Technology is being tested by three different entities in three different countries with brines sampled from the flagship asset, which to-date have returned extremely promising results (99% lithium recovery).
  • Staged & Work Completed with a promising 2022 drill campaign underway designed for resource expansion, that’s already returned high lithium brine results. An Environmental Impact Report has already been completed, and nearby claims have been acquired to secure additional water sources and a location for a future plant and processing facilities.
  • Qualified, Proven Team with extremely strong technical lithium experience that includes minds that were integral to the development of some of the region’s most prominent lithium production operations.

 

 

The Need for Clean(er) Lithium

Before we get to the core of the Lithium South Development (TSXV:LIS) (OTC:LISMF) story, we need to look at the most exciting technological race that’s taking the lithium sector by storm, and how LIS fits into it.

A new report from The Nature Conservancy (TNC) and UCLA recently outlined the need for prioritizing the least impactful methods of lithium extraction to protect the environment and communities.[8]

The questions being raised by TNC are important for markets, because of their reputation for input on assessing the worthiness of companies and “Investing in Nature” in this ESG-focused era.[9]

Voices are growing louder, calling for the methods we use to produce lithium to radically change.

A new lithium technology is drawing heavy investment from major players, such as mining giant Rio Tinto, automaker General Motors, and even the U.S. Energy Department, called direct lithium extraction (DLE).[10]

“[DLE is] such a game changer. There’s huge opportunities.” – U.S. Energy Secretary Jennifer Granholm[11]

Time Magazine recently pointed its readers towards a lithium race in Argentina that could deliver the country a “Sustainable Gold Rush”.[12]

Direct Lithium Extraction (DLE): The Answer?

Embedded within the Time Magazine report was a focus on the work of privately-owned, California-based start-up Lilac Solutions, which in 2021 raised $150 million from investors including Lowercarbon Capital and T. Rowe Price.[13]

This is where Lithium South Development’s (TSXV:LIS) (OTC:LISMF) HMN Li Project begins to shine.

In April 2021, Lilac and Lithium South generated huge optimism, announcing how Lilac’s patented Ion Exchange (IX) technology recovered 99% of the lithium from a synthetic sample of the HMN Li Project brine—identical in chemical composition to that contained within the project’s NI 43-101 Preliminary Economic Assessment (PEA).[14]

But it doesn’t stop there. Lithium South is working with two other groups (not just Lilac) to test the validity of DLE on the HMN Li project, including with Florida-based Eon Minerals Inc.[15] with its in Argentina and with Chemphys and their lab facilities in China.[16]

Using Chemphys’ XFP-Lithium DLE process, test work delivered 80% lithium recovery, which is a near doubling of lithium recovery rates from conventional evaporation extraction.[17]

These results from the DLE testing has been blowing conventional methods out of the water (even though Lithium South is prudently also testing conventional evaporation as a potential method to produce from HMN Li)[18].

How Does Lithium South Development (TSXV:LIS) (OTC:LISMF) Stack Up With Its Neighbors?

Lithium South Development’s (TSXV:LIS) (OTC:LISMF) HMN Li Project is in great company, and surrounded by several major projects.

The HMN Li already has moved forward with a DLE Pilot Plant on deck, a 2019 PEA that gave the project a US$218 million NPV (8%), and with C$64 million on hand, LIS is fully funded to fast-track towards a Feasibility Study.

Where the smart investor will now pay close attention is towards where the company is now, where it’s going, and how it will get there.

If it doesn’t take the project all the way to production on its own, it’s surrounded by stories of major takeout target successes.

According to the company’s calculations, the HMN Li Project is near the top tier in terms of grade and chemistry, meaning it not only has a high grade of lithium that’s ahead of several other big players and their massive projects, but also that it comes with a favourably low magnesium to lithium ratio.

With a M&I Resource of 571,000 T of LCE, the current drilling program is designed to further expand the resource.

And so far the results have looked VERY good.

Recently the company announced a high-grade lithium discovery at its Alba Sabrina claim, with lithium values ranging from 732-772 mg/L lithium[19]—very much on pace with the previous resource’s grades and far above the cut-off grade of 500 mg/L lithium.

Because the drilling campaign’s results are starting to hit the company’s news flow, this is where the smart investor would take notice and not want to be left on the outside looking in as the case for an expanded resource becomes much stronger.

As of August 12, 2022, some might say that Lithium South Development’s (TSXV:LIS) (OTC:LISMF) stock value is an absolute BARGAIN… given that the company’s market cap is less than US$40M, and nearby projects acquired were sold for upwards of 9 digits.

 

The relevance of Lithium South’s high lithium grades cannot be overstated.

Even if we’re looking at conventional brine evaporation ponds, lithium grade is directly related to the size of the ponds. These sizes of ponds account for nearly 50% of the CAPEX of a brine project.

Meaning, the higher the grade, the lower the CAPEX.

Where does Lithium South’s HMN Li stack up amongst its peers?

Now factor in the potential injection of the DLE factor, and the economics start looking even more enticing.

As we’ve seen above, Lilac delivered 99% lithium recovery, while Chemphys delivered 80% lithium recovery, which was DOUBLE that of conventional evaporation tests on the property.

Which means, if one of the three DLE methods ends up winning out, the potential for Lithium South and its flagship asset skyrockets.

Instead of taking 18 months or more to produce lithium through evaporation, Lithium South could potentially produce it within HOURS. Instead of recovering only ~40% of the overall lithium available, DLE could provide as high as 80% or more!

And the potential for losses due to weather goes down to ZERO. Meaning, the project further de-risks itself, should DLE prove itself to be a viable commercial method of producing lithium.

Strong Leadership Team

In order to properly assess and work with a potentially game-changing technology in one of the world’s top lithium production regions, the HMN Li project requires capable hands… Thankfully, Lithium South Development (TSXV:LIS) (OTC:LISMF) is in VERY capable hands.

LIS’s leadership team includes:

Adrian F. C. Hobkirk – President and CEO: Hobkirk has 32 years of experience in the mining and venture capital industry, including extensive experience working in Argentina. He is the co-discoverer of the Dublin Gulch Gold Deposit (Yukon) and the Yarnell Gold Mine (Arizona). He’s explored for precious metals around the world and is currently developing the 1.5-million-ounce AuCuEq Groete Gold Copper Project in Guyana. Hobkirk is the founder of Lithium South Development Corp., having acquired the HMN Lithium Project and managed its development to date.

 Christopher P. Cherry – CFO and Director: Cherry has over 20 years of corporate accounting and audit experience. Formerly an auditor with KPMG, he has extensive corporate experience and has held senior-level positions for several public mining companies. Cherry is a certified general accountant and a chartered accountant.

Yi Hua Dai, PhD – Director: Yi Hua (PhD) founded Chemphys in 1998 to focus on battery quality and high purity lithium processing. He’s a certified Technical and Economic Expert of Sichuan Province and China Non-ferrous Metals Industry Association Expert. He has a proven record of leading the development of lithium manufacturing techniques with 24 patents valid and under application.

Alison Dai – Director: Dai has 9 years of experience in the lithium industry and is responsible for business development and is a director for Chengdu Chemphys Chemical Industry Co., Ltd. In her role at Chemphys, Dai has been involved in developing strategic partnerships, international markets and procurement. Prior to joining Chemphys, Dai was an investment banking analyst at J.P. Morgan Australia in the mining and metals team.

Fernando E. Villarroel – VP & Director Project Development: Villarroel has 12 years of experience in the mining industry in Argentina with a focus on Lithium process development. From 2009 to 2013 he worked with Lithium Americas Corp. (Minera Exar S.A.) as Project Manager which included construction management and commissioning of the initial pilot evaporation facilities and laboratory at the Cauchari Olaroz Lithium Project. He has also acted as a consultant to Neo Lithium and International Lithium Inc. He holds a degree in Industrial Engineering and has specialized training in Data Modeling & Analysis for Business and Engineering from M.I.T.

Marcela Casini – Senior Geologist and Hydrogeologist: Casini has a distinguished career in the lithium exploration and development industry in Argentina, having worked for Rio Tinto as a field geologist exploring salars in the Puna region, as well as on the Minera Exar lithium brine project, a joint venture with Lithium Americas Corp. and Ganfeng Lithium Co, leading the exploration that led the project to the feasibility 2012. From 2019 to 2021 she was responsible for the strategy and development of the production well field, supporting a projected 40,000 tonne per year lithium operation. She’s also has consulted to PepinNini Minerals regarding the exploration and development of lithium resources at the Rincon and Pular salar since 2016.

Vijay Mehta, PhD. – Technical Consultant and Qualified Person: A recognized expert in lithium mining and processing, Dr. Mehta (PhD) brings almost five decades of experience to LIS. His experience includes evaluating the technological and economic feasibility of lithium brine projects around the world. He was the Product and Process Technology Development Leader of FMC Corporation for 30 years and was one of the founding developers of FMC’s lithium plant at the Hombre Muerto Salar, Argentina, which has been in production since 1998. He holds 12 lithium related U.S. patents and has published over 50 technology reports and ten academic papers.

7 Reasons to Put Lithium South Development (TSXV:LIS) (OTC:LISMF) on Your Must-Watch List

 1  The Timing: The lithium market is exploding, with prices skyrocketing over the last two years, and demand expected to more than double by the end of the decade. Meanwhile, analysts are predicting what could be a catastrophic shortfall of lithium supplies in the next few years, unless lithium miners can increase their production to four times its current levels.

 2  Advanced Exploration Stage Project with Great Real Estate: The HMLi Project is located within the mining friendly Salta Province, Argentina, adjacent to a producing Livent property, and surrounded by a near-producing project owned by Korean giant POSCO.

 3  High Quality Brine Resource: The project comes with high lithium brine (756 mg/L), with a low magnesium to lithium ratio (2.6:1), and a M&I Resource of 0.57 Mt LCE, and a projected mine life of 30 years.

 4  Solid PEA Numbers: So far, the PEA done on the project indicates robust economics, with a NPV (8% discount) of US$217 million, that carries a CAPEX of only US$98 million. However, those numbers were calculated in 2019, prior to lithium’s surge to its current LCE market prices that greatly dwarf those previous figures.

 5  Proprietary, ESG-Friendly Technology: Direct Lithium Extraction (DLE) is on the cutting edge of becoming one of the industry’s biggest game changers. It allows for potentially double the lithium recovery without large evaporation ponds. It takes hours, not years, and creates a much smaller environmental footprint, which would appease local communities in ways that conventional production has yet to. Lithium South is evaluating three different unique DLE technologies, as well as the potential for conventional production as a benchmark.

 6  Qualified Proven Team: Extremely strong technical lithium experience, with an office and laboratory located nearby in Salta, Argentina, backed by world-renowned technical consultant and qualified person Vijay Mehda, along with senior geologist/hydrologist Marcela Casini.

 7  Staged & Work Completed: Two production wells have already been drilled and cased. An Environmental Impact Report is currently underway. TEM survey results confirm further resource expansion potential. The company has aggressively acquired nearby claims to secure water sources and a location of future plant and processing facilities.

Now that you’ve digested the fruits of our research, it’s time to follow up with some research of your own.

NOW IS THE PERFECT TIME for smart investors to seriously follow the rapidly Lithium South Development (TSXV:LIS) (OTC:LISMF) story.

LIS is actively working to expand its already impressive resource in one of the world’s most sought after lithium jurisdictions, and is at the forefront of proving the viability of potentially industry changing DLE technology.

So, do your own due diligence, and don’t forget to click here to sign up for the Lithium South’s newsletter to make sure you don’t miss out on any news and milestones along the way to becoming the next darling of the lithium sector.

USA News Group
Editorial Staff

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Lithium South Development Corporation advertising and digital media from the company directly. There may be 3rd parties who may have shares of Lithium South Development Corporation, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Lithium South Development Corporation which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares Lithium South Development Corporation at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Lithium South Development Corporation and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

[1] https://www.mining.com/global-lithium-production-hits-record-high-on-electric-vehicle-demand/

[2] https://elements.visualcapitalist.com/lithium-consumption-has-nearly-quadrupled-since-2010/

[3] https://www.benchmarkminerals.com/membership/analysis-lithium-industry-needs-42-billion-to-meet-2030-demand/

[4] https://www.sciencedirect.com/science/article/abs/pii/S0959652621011732

[5] https://www.benchmarkminerals.com/membership/analysis-lithium-industry-needs-42-billion-to-meet-2030-demand/

[6] https://www.globenewswire.com/en/news-release/2022/03/11/2401706/29442/en/Global-Lithium-Market-Expected-to-Reach-8-2-Billion-by-2028-Grand-View-Research-Inc.html

[7] https://www.mining-technology.com/analysis/lithium-price-challenges/

[8] https://www.nature.org/en-us/newsroom/ca-lithium-extraction/

[9] https://www.nature.org/content/dam/tnc/nature/en/documents/TNC-INVESTING-IN-NATURE_Report_01.pdf

[10] https://www.reuters.com/business/sustainable-business/new-lithium-technology-can-help-world-go-green-if-it-works-2022-04-07/

[11] https://www.reuters.com/business/sustainable-business/new-lithium-technology-can-help-world-go-green-if-it-works-2022-04-07/

[12] https://time.com/6200372/lithium-mining-technology-argentina-gold/

[13] https://www.cnbc.com/2021/09/22/lilac-raised-150-million-for-sustainable-lithium-extraction-tech.html

[14] https://www.lithiumsouth.com/posts/lilac-solutions-achieves-99-lithium-recovery-with-ion-exchange-process/

[15] https://www.lithiumsouth.com/posts/eon-minerals-inc-to-evaluate-hmn-brine-using-direct-lithium-extraction-technology/

[16] https://www.prnewswire.com/news-releases/lithium-south-development-corporation-doubling-of-lithium-recovery-from-brine-with-chemphys-process-301248906.html

[17] https://www.lithiumsouth.com/posts/doubling-of-lithium-recovery-from-brine-with-chemphys-process/

[18] https://www.lithiumsouth.com/posts/evaporation-test-work-underway-at-hmn-li-project/

[19] https://www.lithiumsouth.com/posts/high-grade-lithium-discovery-at-alba-sabrina-claim-block/

Editor by — April 27, 2024 By Editor in Uncategorized
Spat Between Silicon Valley Giants Dogecoin vs Bitcoin Sparks Debate Over Each Coin’s Potential

USA News Group – Bitcoin (BTC) or Dogecoin (DOGE)? Which cryptocurrency will prevail and be embraced as the “currency of the internet and the people”? This question recently caused a brief but intense spat between a pair of Silicon Valley giants: Jack Dorsey, the co-founder of Twitter Inc. (NYSE:TWTR) and CEO of Block, Inc. (NYSE:SQ), and Vlad Tenev, CEO of Robinhood Markets, Inc. (NASDAQ:HOOD). Dogecoin has surged over the last two years in popularity and mindshare, to knock at the door of #2 cryptocurrency Ethereum. Soon after SpaceX CEO Elon Musk began making a serious play to acquire Twitter, DOGE prices shifted, causing Forbes to infer Dogecoin as a ‘Proxy for Twitter Stock’. As the debate rages onward, cryptomining specialists have benefitted such as Neptune Digital Assets Corp. (TSXV:NDA) (OTC:NPPTF), and Hello Pal International Inc. (CSE:HP) (OTC:HLLPF) which recently combine its crypto mining capabilities with its successful video livestreaming and matching businesses.

The newly launched DogeChat and DoggeChat apps from Hello Pal International Inc. (CSE:HP) (OTC:HLLPF) are set to allow users to match and/or video chat with other individual users from across the globe. When a connection is made, 1-on-1 video calls will generate revenues on a per-minute basis, paid for by the call’s initiator to the call’s receiver—now with the option to pay in crypto, which Hello Pal also is in the business of mining.

“We expect these apps to be very synergistic to our current livestreaming and crypto-mining operations,” said KL Wong, Founder and Chairman of Hello Pal. “They will not only bring into our existing ecosystem new users from different markets, but also allow us to start implementing our goal to make the use of cryptocurrency more widespread in the world, starting with our users.”

Where DogeChat payments will be made in DOGE and other cryptocurrencies, DoggeChat payments will be in fiat currencies made through Apple Pay and Google Pay. First to launch will be DoggeChat, before DogeChat is launched at a later date, using the same user pool. However,

regular users of DoggeChat will be incentivized in various ways to switch to DogeChat.

Hello Pal made history back in May 2021 by becoming the market’s first listed company focused on DOGE mining. Reaction to the announcement was swift, causing a surge in traffic so heavy it temporarily caused a website outage.

Both the DoggeChat and DogeChat launches represent Hello Pal’s market expansion into the burgeoning 1-on-1 video chatting space, as well as its foray into the North American market.

More significantly, it also represents their plan to start incorporating cryptocurrency payments into their social and livestreaming businesses.

Meanwhile, in terms of revenues from cryptocurrency mining, Hello Pal and Neptune Digital Assets Corp. (TSXV:NDA) (OTC:NPPTF) have similar market caps and both recently reported strong revenues from their operations.

Back in February Hello Pal, was still transitioning its mining operations out of China, while increasing its mining assets and improving upon its crypto-mining operations infrastructure.

“Our livestreaming operations continue to deliver strong operating results as we continue to diversify outside of China,” said KL Wong. “With our focus on cryptocurrency mining operations, we anticipate that revenue and profit will continue in an upward trend.”

Whereas Hello Pal focuses its mining on DOGE, Neptune Digital Assets focuses more on BTC.

During Q1 2022, Neptune Digital Assets set a fiscal quarter record with C$13 million in comprehensive income, derived from not only mining, but staking and DeFi earnings and crypto fund investment as well.

“We hope to see the general crypto space grow as we move forward into 2022 and our Bitcoin mining, staking, and DeFi earnings to increase accordingly as we grow those arms of the business,” stated Cale Moodie, Neptune CEO. “We anticipate another 53 petahash of mining capacity to come online in Q2 thus growing our Bitcoin earnings. We are staying true to our diversified model and will continue to manage our risk while maximizing our earnings across the board.”

Which brings things back to the feud on Twitter Inc. (NYSE:TWTR) between Jack Dorsey CEO of Block, Inc. (NYSE:SQ), and Vlad Tenev, CEO of Robinhood Markets, Inc. (NASDAQ:HOOD).

Tenev began the conversation, positing in a Tweet: “Can #Doge truly be the future currency of the internet and the people? As we added the ability to send/receive DOGE on Robinhood, I’ve been thinking about what that would take.”

He went on to claim that Dogecoin could outperform Visa with respect to transaction speedsd, and that the crypto coin’s transaction speeds would eventually surpass the credit card giant’s current 65,000 transactions per second (TPS) capabilities.

“Doge would need to be able to significantly outperform Visa, which entails increasing throughput by at least 10000x,” wrote Tenev.

While there was plenty of support for Tenev’s musings, others on Twitter began to push back, including the social media platform’s co-founder and former CEO, Jack Dorsey, with pointed barbs that reflected some of the audience’s skepticism due to Robinhood’s more recent dependence on DOGE for its revenue and profits.

Dorsey responded to Tenev’s final tweet with a snarky, “u thirsty?”, to which Tenev fired back with “U mad?”

Not leaving it alone, Dorsey replied, “nah I’m good I don’t use Robinhood.”

Tenev cleverly got the final word, capitalizing on an opportunity for Robinhood plug, replying “you would pay less for your bitcoin if you did!”

Twitter Inc. (NYSE:TWTR) itself isn’t playing a spectator in the cryptocurrency scene, by working with online payments firm Stripe to become the first company to integrate a new payment method that makes payouts in crypto through the stablecoin USDC. Beginning right away, Twitter will let a certain number of creators receive their earnings from its paid Ticketed Spaces and Super Follows features in USDC.

Block Inc. (NYSE:SQ) CEO Dorsey has gone all in on Bitcoin, with his departure from Twitter leading Bloomberg’s Businessweek to claim his intention is become Bitcoin’s “Spiritual Leader.”

His company is set to work with cryptocurrency storage company Blockstream to construct a solar-powered BTC mining facility in Texas. The 3.8-megawatt (MW) facility will be outfitted with Tesla’s solar photovoltaic cell array and a 12 MWh Megapack.

As some were criticizing Tenev for being biased in his support of DOGE, the seemingly critical anti-Dogecoin and anti-Ethereum statements of Dorsey while being hyper-focused on BTC could also be seen as biased.

Article Source: https://usanewsgroup.com/2020/11/16/live-streaming-is-taking-the-market-by-storm/

 

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Hello Pal International Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Hello Pal International Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Hello Pal International Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Hello Pal International Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Editor by — April 27, 2024 By Editor in Uncategorized

Rare Diseases and Orphan Drugs shows that much of what we now know about common diseases has been achieved by studying rare diseases. It proposes that future advances in the prevention, diagnosis, and treatment of common diseases will come as a consequence of our accelerating progress in the field of rare diseases.

Understanding the complex steps in the development of common diseases, such as cancer, cardiovascular disease, and metabolic diseases, has proven a difficult problem. Rare diseases, however, are often caused by aberrations of a single gene. In rare diseases, we may study how specific genetic defects can trigger a series of events that lead to the expression of a particular disease. Often, the disease process manifested in a certain rare disease is strikingly similar to the disease process observed in a common disease.

This work ties the lessons learned about rare diseases to our understanding of common ones. Chapters covering the number of common diseases are minimized, while rare diseases are introduced as single diseases or as members of diseases classes. After reading this book, readers will appreciate how further research into the rare diseases may lead to new methods for preventing, diagnosing, and treating all diseases, rare or common.

For more information on this sector, please enter your email address in the box provided on this page and we will be happy to send you information as it becomes available to us

Editor by — April 27, 2024 By Editor in Uncategorized

One of the best kept secrets among most seasoned biopharma investors is the lucrative and enticing potential for treating rare diseases with orphan drugs.

PAY ATTENTION: We’ve identified a rare-disease, orphan-drug company declared by multiple analysts as a STRONG BUY* with price targets in excess of 350%—and that company is Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX). – This company is extremely undervalued, analysts agree as you will see below, and we personally think it is a huge bargain at this price point with major upside potential in the very near future.

Market research firm EvaluatePharma projects that worldwide orphan-drug sales will DOUBLE by 2026 to hit US$268 billion[1], and Prophecy Market Insights projects it will be more than DOUBLE of that, hitting US$547.5 billion by 2030, growing at a RAPID 13.1% CAGR.[2] 

What is an Orphan Drug?

Orphan drugs are medicines developed to help treat, prevent or diagnose rare “orphan” diseases, which are conditions that each affect fewer than 200,000 people in the U.S. Today, about 600 orphan drugs are approved by the U.S. Food and Drug Administration (FDA) to treat these difficult and rare diseases. In order to spur pharmaceutical companies to develop more Orphan Drugs, Congress passed the Orphan Drug Act in 1983. This law encourages drug makers to research and manufacture orphan drugs by giving them tax incentives, subsidies for clinical research. This program has been very successful and very lucrative.

* Sources: [3],[4],[5],[6],[7]

Source: NASDAQ.COM

Source: https://www.marketbeat.com/stocks/NASDAQ/QNRX/price-target/

Analysts are bullish on QNRX and the sector as you can see by the above average price target of $6.50, with a low target of $5.00 and and a high target of $8.00.

So, let’s look at some of the major factors behind this rare disease market that has been incentivized from what was once a barren land into totally fertile ground.

Roughly 30 million Americans suffer from 7,000 or so rare diseases.[8]

And to address these patients, the US FDA funds research in rare diseases through programs like the Orphan Products Grants Program, by implementing the Orphan Drug Act, and reviewing and granting designations to Rare Disease Drugs, Rare Pediatric Diseases, and Devices. To sweeten the pot, the FDA also offers seven years for Orphan Drug Exclusivity (ODE), giving two whole years more of market exclusivity than New Chemical Entity Exclusivity (NCE).[9]  

Because of this, biopharma companies are VERY attracted to the orphan-drug market. After decades since the passage of the Orphan Drug Act, the FDA has given orphan status to over 500 drugs[10], while the EU has given orphan designation to over 2,200 medicines.[11] 

As of 2020, the FDA had approved drugs and biologics for over 800 rare disease indications.[12] Rare-disease drugmakers are BIG business, and even mean a lot to BIG Pharma. In 2021, AstraZeneca both acquired rare disease drug makers (Alexion) for US$39 billion[13], and agreed to pay up to $3.6 billion for the rights to a promising drug for another rare disease.[14]

UCB recently bought rare disease Zogenix for up to US$1.9 billion,[15] Italian pharma group Recordati closed out 2021 by signing an agreement to buy UK-based EUSA Pharma for an enterprised value of nearly US$850 million.[16]

“Orphans are wicked hot.”

– Dr. Tim Coté,
Former FDA official, and CEO of Only Orphans Cote LLC [17]

30-Second Intro: A Special Specialty Pharma Co.

  • Tightly-held share structure, and currently valued at less than $11.5M
  • Trading at less than $1.35.
  • Multiple analysts have given QNRX a ‘BUY’ or ‘STRONG BUY’ Rating.
  • Publicly shared analyst price targets avg $6.50 per share and as high as $8 per share.[18]
  • Rare and Orphan Disease Focused specialty pharmaceutical company.
  • Innovative Pipeline with three products targeting a broad number of rare and orphan diseases, including Rare Pediatric Designations.
  • Plans in placeto establish a sales infrastructure to commercialize its products in both the USA and Europe.
  • Targeting US/EU Approvals in 2024, 2025, and 2026.
  • Established Strategic licensing partnerships for entry into multiple markets.
  • Strong Key Opinion Leader (KOL) support.
  • Experienced Management Team.

Capital Structure Statistics
Total Shares Outstanding — 8,350,000
Average Volume — 2.47 Million
Market Cap — $11.2 Million
Institution Ownership — 10.57%

QUICK RUNDOWN: THE PIPELINE

Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) is focused on developing innovative treatments for rare and orphan diseases, and has a pipeline that comprises three unique products (including QRX003, QRX004, and QRX006) that collectively have the potential to target a broad number of indications.

**FLAGSHIP** QRX003: Netherton Syndrome

QRX003 is under development as a potential therapy for the treatment of Netherton Syndrome (NS)— a rare, hereditary skin disorder leading to severe skin barrier defects and recurring infections, as well as a pronounced predisposition to allergies, asthma and eczema.

Patients also often suffer from severe dehydration, chronic skin inflammation and stunted growth.

People with Netherton Syndrome have too few layers of their outer skin (stratum corneum) so the skin does not perform its primary function as a protective barrier.

Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.

QRX003 is a once-daily topical lotion that offers a combination of a broad-spectrum serine protease inhibitor, and is formulated with Quoin Pharmaceuticals’ (NASDAQ:QNRX) proprietary Invisicare® technology. 

When applied daily to the skin, the active ingredient in QRX003 leads to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier, while also acting as a potent anti-inflammatory and antioxidant.

QRX003 is also being developed to target Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma.

QRX004: Epidermolysis Bullosa

QRX004 is also a topical lotion made with Quoin Pharmaceuticals’ (NASDAQ:QNRX) proprietary Invisicare® technology, initially under development as a potential treatment for a group of rare and genetic skin disorders, in which the skin is so trauma or friction, which can have devastating results, cause severe pain, blistering, scarring, infection and immobility.

Known as Recessive Dystrophic Epidermolysis Bullosa (RDEB), it’s diagnosed at infancy and accompanied by a high mortality rate – 76% do not live beyond their 30s.

The cost of bandaging alone can exceed $10,000 per month. 

Quoin Pharmaceuticals’ (NASDAQ:QNRX) QRX004 is designed for the creation of robust and sustained type VII collagen, and for improved wound closure, reduced blistering and stronger skin.

QRX006: Undisclosed Rare Skin Disease

QRX006 is another a topical lotion that Quoin Pharmaceuticals (NASDAQ:QNRX) is developing for an, as of yet, undisclosed rare skin disease.

It contains two separate active ingredients and is designed to be applied directly to the affected site over a prescribed period.

Currently available treatment involves the daily systemic administration (oral and IV) of the same two active ingredients that are in QRX006 over a period of several weeks.

This treatment is both cumbersome and costly for patients and healthcare providers and can lead to significant unpleasant side effects, often resulting in patients discontinuing treatment.

QRX006 is designed to reduce the side effects associated with systemic treatment and enable patients to apply the product directly themselves without the need for daily visits to a hospital or clinic. 

Quoin Pharmaceuticals (NASDAQ:QNRX) applied for a patent for QRX006 in mid-2021.

AT THIS POINT we have identified a publicly-traded company with multiple assets in the pipeline and in planning stages of establishing sales infrastructure for the USA and Europe… and that company is
Quoin Pharmaceuticals (NASDAQ:QNRX)

Strategic Partnerships

Quoin Pharmaceuticals (NASDAQ:QNRX) has established partnerships with other companies and advocacy organizations.

FIRST was established to help individuals and families affected by ichthyosis. 

The organization educates, inspires, and connects families and individuals affected by Ichthyosis and related skin types. Services include biennial national family conferences, regional meetings, a regional support network, publications, advocacy and a research program.

Quoin Pharmaceuticals (NASDAQ:QNRX)  has in-licensed a bi-functional biologic from QUT for the treatment of Netherton Syndrome.

Quoin Pharmaceuticals (NASDAQ:QNRX) has entered into a licensing and distribution agreement with GenPharm for the Middle East.

AFT is Quoin’s licensing and distribution partner for Australia and New Zealand.

Feature Company:

Quoin Pharmaceuticals
Trade Symbol – NASDAQ:QNRX
Market Cap – ~$11.3 Million
Shares Outstanding: 8.35M

Leaders With Experience

Quoin Pharmaceuticals (NASDAQ:QNRX) is led by a group of seasoned management, board & advisors with particular skill sets and significant wins in the pharmaceutical sector. 

Co-Founder, Chairman, CEO & Director Dr. Michael Myers brings more than 30 years of experience in the drug delivery and specialty pharmaceutical sectors. He’s served as CEO of Innocoll, Inc., where he was responsible for taking that company public in 2014, and also served in presidential roles for West Pharmaceutical Services, Fuisz Technologies (Biovai), and executive positions in Flamel Technologies and Elan Corporation. Dr. Myers also serves on the Board of Directors for Sonoran Biosciences as well as on the Advisory Boards for two Penn State startup companies, Cranial Devices and Gradient T.

Co-Founder, COO & Director Denise Carter also has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. Carter and Myers have both worked at Innocoll, Inc., where she served as executive vice president of business development of the drug delivery division. Ms. Carter also held executive positions at Eurand and Fuisz Technologies (Biovail).  

Among the members of the Board is Director Dr. Dennis H. Langer, MD, JD, whose spent over 35 years in the pharmaceutical industry at Eli Lilly, Abbott, Searle, GSK, and served as President at Dr. Reddy’s, NA. He’s also served as Director at Sirna Therapeutics (acquired by Merck), Ception Therapeutics (acquired by Cephalon), Transkaryotic Therapies (acquired by Shire), Pharmacopeia (acquired by Ligand), Cytogen (acquired by EUSA Pharma) and Delcath Systems. He currently serves as a Director at Myriad Genetics, Dicerna Pharmaceuticals and Pernix Therapeutics.

 

Before You Go…
REMEMBER THESE 5 POINTS

  1. Quoin Pharmaceuticals (NASDAQ:QNRX) and its proprietary Invisicare® technology are well- positioned to succeed in 2022.
  2. Analysts currently covering the company are unanimous in their BUY recommendations.
  3. QNRX is a VERY tightly held stock, with only 8.35M shares outstanding, and 10.57% institutional ownership.
  4. It currently trades at less than $1.30 per share, but has an average price forecast of $6.50, with estimates between $5-$8 for 2022.
  5. Big Pharma is spending BILLIONS to acquire, retain, and develop rare disease/orphan drug treatments.

So putQuoin Pharmaceuticals (NASDAQ:QNRX) on your radar, and do your own research to see why we felt it so necessary to bring it to your attention TODAY.

SOURCES CITED:

[1] https://www.pharmaceuticalcommerce.com/view/evaluate-pharma-predicts-a-981-billion-global-pharma-market-for-2021-up-14-3-

[2] https://www.globenewswire.com/news-release/2021/02/24/2181634/0/en/Global-Rare-Disease-Market-is-estimated-to-be-US-547-5-billion-by-2030-with-a-CAGR-of-13-1-during-the-forecast-period-by-PMI.html

[3] https://www.nasdaq.com/market-activity/stocks/qnrx/analyst-research

[4] https://www.wsj.com/market-data/quotes/QNRX/research-ratings

[5] https://www.marketwatch.com/investing/stock/qnrx/analystestimates

[6] https://www.investorsobserver.com/news/stock-update/analyst-rating-will-quoin-pharmaceuticals-ltd-adr-qnrx-stock-do-better-than-the-market

[7] https://biotuesdays.com/2022/01/07/maxim-starts-quoin-pharma-at-buy-pt-5/

[8] https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases

[9] https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity

[10] https://rarediseases.info.nih.gov/diseases/fda-orphan-drugs

[11] https://www.ema.europa.eu/en/documents/leaflet/leaflet-orphan-medicines-eu_en.pdf

[12] https://www.fda.gov/news-events/fda-voices/rare-disease-day-2020-fda-continues-important-work-treatments-rare-diseases

[13] https://www.fiercepharma.com/pharma/astrazeneca-fresh-from-alexion-deal-repelled-7-6b-buyout-rare-disease-specialist-sobi-report

[14] https://www.standard.co.uk/business/pharmaceuticals/astrazeneca-covid19-ionis-liver-rare-diseases-alexion-soriot-b970433.html

[15] https://www.fiercepharma.com/pharma/ucb-buys-rare-disease-drugmaker-zogenix-for-up-to-1-9b-bolsters-epilepsy-position

[16] https://www.reuters.com/markets/deals/recordati-buy-eusa-pharma-847-mln-boost-rare-disease-offering-2021-12-03/

[17] https://www.npr.org/sections/health-shots/2017/01/17/509506836/drugs-for-rare-diseases-have-become-uncommonly-rich-monopolies

[18] https://www.nasdaq.com/market-activity/stocks/qnrx/analyst-research 

DISCLAIMER:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is NOT a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has not been paid a fee for profiling Quoin Pharmaceuticals on this website or in other market publications, but  . There we doo own shares of Quoin Pharmaceuticals which were purchased in the open market, which we plan to sell immediately and will sell in the immediate future. There may also be 3rd parties who may have purchased shares of Quoin Pharmaceuticals, and may liquidate their shares which could have a negative effect on the price of the stock. The simple fact that we own shares of Quoin Pharmaceuticals constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQ, our associates, employees and friends also reserve the right to buy and sell, and will buy and sell shares of Quoin Pharmaceuticals at any time hereafter without any further notice. Let this disclaimer serve as notice that all material disseminated by MIQ has not been approved by Quoin Pharmaceuticals; this is not a paid advertisement, but we own shares of the Quoin Pharmaceuticals which were purchased in the open market that we will sell commencing immediately, and we also reserve the right to buy and sell shares of the company in the open market and we will buy and sell shares in the open market commencing immedaitely.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Editor by — April 27, 2024 By Editor in Uncategorized
error: Content is protected !!